Skip to content

Innoviva, Inc. INVA Return on equity

Return on equity at other companies

Pfizer logo
PfizerPFE
10.6%
Merck & Co. logo
Merck & Co.MRK
19%-20.3pp
AbbVie logo
AbbVieABBV
89%+32.7pp
Insmed logo
InsmedINSM
-294.5%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-67.6%-20.3pp
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-55.2%+8.0pp

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.4B+9.7%
P/E3.5×
P/S4.1×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s return on equity?
Innoviva, Inc. (INVA) reported return on equity of 29.1% in Q4 2025.
What is the long-term trend for Innoviva, Inc.'s return on equity?
Over 2 years (2020 to 2025), Innoviva, Inc.'s return on equity has grown at a -35.0% compound annual growth rate (CAGR), from 68.9% to 29.1%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.